AIV Logo AIV Assistant

Loading...

 Logo ReShape Lifesciences Inc. - RSLS Open ReShape Lifesciences Inc. in new tab

3.92 USD
P/E
0.01
EPS
-830.44
P/B
-0.45
ROE
-120.16
Beta
1.90

3.9200 USD

3.920 USD

Daily: +0.00%
Key Metrics

Earnings date: Nov. 13, 2025

P/E: 0.01

EPS: -830.44

Book Value: -8.67

Price to Book: -0.45

Debt/Equity: 10.57

% Insiders: 10.626%

Growth

Revenue Growth: -0.43%

Estimates

Forward P/E: -10.89

Forward EPS: -0.36

DCF Valuation

Tweak assumptions to recompute fair value for ReShape Lifesciences Inc. (RSLS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

 Logo About ReShape Lifesciences Inc. - (RSLS)

Country: United States

Sector: Health Care

Website: http://www.reshapelifesciences.com

As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in Irvine, California.

Exchange Ticker
PNK (United States) RSLS

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
July 25, 2019 0.100000
Dec. 23, 2022 0.020000
Sept. 23, 2024 0.020000
May 9, 2025 0.040000
Aug. 15, 2025 0.250000
Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion